Last reviewed · How we verify

Zavzpret (zavegepant)

Pfizer · FDA-approved active Quality 68/100

Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment.

ZAVZPRET is a nasal spray CGRP receptor antagonist indicated for acute migraine treatment in adults with or without aura. The drug demonstrates rapid onset (Tmax ~30 minutes) with moderate bioavailability (5%) and high protein binding (90%), requiring careful management of transporter-mediated drug interactions. Key safety considerations include hypersensitivity reactions including anaphylaxis, and dose adjustments may be needed in moderate hepatic impairment and severe renal impairment. ZAVZPRET offers a non-oral acute migraine option but is not indicated for preventive treatment.

At a glance

Generic namezavegepant
SponsorPfizer
Drug classCGRP receptor antagonist
TargetCalcitonin gene-related peptide (CGRP) receptor
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval2023

Mechanism of action

Zavegepant works by antagonizing the calcitonin gene-related peptide (CGRP) receptor, a mechanism implicated in migraine pathophysiology. CGRP is a neuropeptide involved in pain transmission and neurogenic inflammation associated with migraine. By blocking CGRP receptor signaling, zavegepant reduces the neurobiological cascade that leads to migraine symptoms.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: